The model validation revealed comparable results as the model calibration for both crops (Tables 2, 3).
Both objective anthropometric measures [25], [26] and computational models [19] have revealed comparable heterogeneity for Caucasian, African and East Asian faces.
Biodistribution of [68Ga]AATZA-MG and [111In]AATZA-MG in the tumour xenograft model revealed a comparable uptake in the CCK2+ tumour (68Ga = 1.5 %ID/g; 111In = 1.74 %ID/g), which is about fourfold higher than in the CCK2− tumour (68Ga = 0.44 %ID/g; 111In = 0.33 %ID/g).
The risk estimates of age, number of pregnancies and menopausal status in a logistic regression model including OC and MHT as separate ever/never variables revealed comparable OR with the model in which both types of use were operationalized in one variable.
Excluding participants with a follow-up time of less than two years (71 cases, 80 non-cases) revealed comparable hazard ratios (model 1: HR: 1.03, 95% CI: 1.01-1.04, model 5: HR: 1.02, 95% CI: 1.00-1.03) and p values (model 1: <0.001 and model 5: 0.02) for the UPMS score.
Consequently, compound 4 revealed comparable or better safety profile than model antiepileptic drugs (AEDs): ethosuximide, lacosamide, and valproic acid.
Furthermore, analysis of median fluorescence revealed comparable GFP fluorescence in LT-, ST-HSC, CMP, GMP and MEP indicating that the R26-iM2 effector mouse model directed similar transgene activation levels to these populations (Supporting Information Fig S1B).
However, both groups revealed comparable PD reductions and only minor improvements in mean BOP scores [55].
Competitive binding and treatment assays revealed comparable biologic properties for F-SKI249380 and the parent drug.
